Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-05-27
2011-12-27
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S210000
Reexamination Certificate
active
08084469
ABSTRACT:
The invention relates to compounds of the formula (I)to processes for the preparation thereof, and to the use thereof for the treatment of cardiovascular disorders and tumor disorders.
REFERENCES:
patent: 5767144 (1998-06-01), Winn et al.
patent: 2001/0044454 (2001-11-01), Nantermet et al.
patent: 2006/0004049 (2006-01-01), Yao et al.
patent: 2008/0003214 (2008-01-01), Cezanne et al.
patent: 2009/0306139 (2009-12-01), Heimbach
patent: 2010/0305111 (2010-12-01), Heimbach
patent: 2011/0021489 (2011-01-01), Heimbach et al.
patent: 2706991 (2009-06-01), None
patent: 9736873 (1997-10-01), None
patent: 03/039440 (2003-05-01), None
patent: 2006002349 (2006-01-01), None
patent: 2006002350 (2006-01-01), None
patent: 2006/012226 (2006-02-01), None
patent: 2006/020598 (2006-02-01), None
patent: 2007/038138 (2007-04-01), None
patent: 2007/101270 (2007-09-01), None
patent: 2007089683 (2007-09-01), None
patent: 2007/130898 (2007-11-01), None
patent: 2009/068214 (2009-07-01), None
Vu et al., “Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation,” Cell, 64:10547-1068 (1991).
Bhatt et al., “Scientific and Therapeutic Advances in Antiplatelet Therapy,” Nat. Rev. Drug Discov., 2:15-28 (2003).
Kahn et al., “Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin,” J. Clin. Invest., 103:879-887 (1999).
Derian et al., “Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates,” J. Pharmacol. Exp. Ther., 304:855-861 (2003).
Dellinger et al., “Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock,”Crit. Care Med., 32:858-873 (2004).
Mochizuki et al., “Design, synthesis, and biological activity of piperidine diamine deriviatives as factor Xa inhibitor,” Bioorg. Med. Chem. Lett , 18:782-787 (2008).
U.S. Appl. No. 12/323,454, filed Nov. 25, 2008.
U.S. Appl. No. 12/788,641, filed May 27, 2010.
J.C. Barrow et al., “Discovery and Initial Structure-Activity Relationships of Trisubstituted Ureas as Thrombin Receptor (PAR-1) Antagonists,” Bioorganic & Medicinal Chemistry Letters, 11: 2691-2696 (2001).
Chackalamannil, Samuel: “Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects”, Journal of Medicinal Chemistry, 49(10): 5389-5403 (Sep. 7, 2006).
Diaz, J. L. et al., “Fast efficient access to a family of multifunctional 1,3,5-trisubstituted piperidines”, Synthetic Communications, 38: 2799-2813 (Jan. 2008).
McAtee J. J. et al., “Development of potent and selective small-molecule human Urotensin-II antagonists,” Bioorganic and Medicinal Chemistry Letters, 18: 3500-3503 (2008).
Morissette et al., High-throughput cyrstallization: polymorphs, salts ,co-crystals, and solvates of pharmaceuitical solids, Advanced Drug Delivery Reviews, 56: 275-300 (2004).
Vippagunta et al., abstract, Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48:3-26 (2001).
Golub et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring,” Science, vol. 286: 531-537 (1999).
Lala et al., “Role of nitric oxide in tumor progression: lessons from experimental tumors,” Cancer and Matastasis Reviews, 17(1), 91-106 (1998).
Bender Eckhard
Buchmüller Anja
Cancho Grande Yolanda
Gerdes Christoph
Gericke Kersten Matthias
Bayer Pharma Aktiengesellschaft
Habte Kahsay T
LandOfFree
Substituted piperidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted piperidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4312421